よむ、つかう、まなぶ。
09参考資料１－３ ９価ヒトパピローマウイルス（ HPV ）ワクチン ファクトシート (48 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000192554_00024.html |
| 出典情報 | 厚生科学審議会予防接種・ワクチン分科会 予防接種基本方針部会（第49回 10／4）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
2056
176. Mejilla, A., et al. (2017). Human papilloma virus (HPV) vaccination: Questions and
2092
of Gynecologic Oncology Guideline. J Gynecol Oncol 30(2): e31.
2057
answers.Can Pharm J (Ott). 150: 306-315.
2093
https://www.ncbi.nlm.nih.gov/pubmed/30740959
2058
https://www.ncbi.nlm.nih.gov/pubmed/28894500
2094
189. Jiang, Y., et al. (2019). Cost-effectiveness and value-based prices of the 9-valent human
2059
177.
2095
papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling
2060
https://www.healthlinkbc.ca/healthlinkbc-files/hpv-vaccines
2061
178.
2062
British Colombia HealthLink BC.(2019). Human Papillomavirus (HPV) Vaccines.
2096
analysis. BMJ Open 9(11): e031186. https://www.ncbi.nlm.nih.gov/pubmed/31767588
2097
190. Meeting of the Strategic Advisory Group of Experts on Immunization, October 2019:
https://www.merck.ca/static/pdf/GARDASIL_9-PM_E.pdf
2098
conclusions and recommendations. (2019).
Merck
Canada
Inc.
(2020).
PRODUCT
MONOGRAPH
GARDASIL®9.
2063
179. Public Health Agency of Canada.(2019). Public Health Agency of Canada. Canadaʼs
2099
Weekly Epidemiological Record. 2019, 94, 541‒560.
2064
Provincial and Territorial Routine (and Catch-up) Vaccination Schedule for Infants and
2100
https://www.who.int/wer/2019/wer9447/en/
2065
Children. https://www.canada.ca/content/dam/phac-aspc/documents/services/provincial-
2101
191.
2066
territorial-immunization-information/childhood-vaccination-schedule-august-2019.pdf
2102
(2019). 19th meeting of the European Technical Advisory Group of Experts on immunization
2067
180.
Patel, C., et al. (2018). The impact of 10 years of human papillomavirus (HPV)
2103
(ETAGE) (2019).
2068
vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
2104
https://www.euro.who.int/__data/assets/pdf_file/0009/424647/ETAGE-2019-report.pdf
2069
Euro Surveill 23(41).
2105
2070
181.
2071
Papillomavirus（HPV）.(2018). Factsheet Human Papillomavirus（HPV）.
2072
http://ncirs.org.au/ncirs-fact-sheets-faqs/human-papillomavirus-vaccine-australians
2073
182. Merck Sharp & Dohme (Australia) Pty Limited. (2017). PRODUCT INFORMATION
2074
GARDASIL®9. https://www.tga.gov.au/sites/default/files/auspar-human-papillomavirus-9-
2075
valent-vaccine-170103-pi.pdf
2076
183.
2077
(2017). Introduction of GARDASIL® 9 In a 2-Dose Schdule under the School-based National
The European Technical Advisory Group of Experts on Immunization (ETAGE).
National Centre for Immunisation Research and Surveillance. Factsheet Human
Australian Technical Advisory Group on Immunisation (ATAGI). Clinical Advice.
2078
Immunisation Program (NIP). https://www.health.gov.au/sites/default/files/atagi-advice-
2079
gardasil9.pdf
2080
184. The New Zealand Ministry of Health.HPV vaccine.
2081
https://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/hpv-
2082
immunisation-programme/hpv-vaccine
2083
185. The Immunisation Advisory Centre . Gardasil 9 Schedule and administration.
2084
https://www.immune.org.nz/vaccines/available-vaccines/gardasil-9
2085
186.
2086
SHEET GARDASIL® 9
Merck Sharp & Dohme (New Zealand) Limited. (2019).NEW ZEALAND DATA
2087
https://www.medsafe.govt.nz/profs/Datasheet/g/gardasil9inj.pdf
2088
187.
2089
Introduction of Vaccination to the National Immunization Program in Korea: an Overview. J
Kim, M. A., et al. (2018). Current Status of Human Papillomavirus Infection and
2090
Korean Med Sci 33(52): e331.
2091
188. Min, K. J., et al. (2019). Clinical guideline for 9-valent HPV vaccine: Korean Society
95
96
176. Mejilla, A., et al. (2017). Human papilloma virus (HPV) vaccination: Questions and
2092
of Gynecologic Oncology Guideline. J Gynecol Oncol 30(2): e31.
2057
answers.Can Pharm J (Ott). 150: 306-315.
2093
https://www.ncbi.nlm.nih.gov/pubmed/30740959
2058
https://www.ncbi.nlm.nih.gov/pubmed/28894500
2094
189. Jiang, Y., et al. (2019). Cost-effectiveness and value-based prices of the 9-valent human
2059
177.
2095
papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling
2060
https://www.healthlinkbc.ca/healthlinkbc-files/hpv-vaccines
2061
178.
2062
British Colombia HealthLink BC.(2019). Human Papillomavirus (HPV) Vaccines.
2096
analysis. BMJ Open 9(11): e031186. https://www.ncbi.nlm.nih.gov/pubmed/31767588
2097
190. Meeting of the Strategic Advisory Group of Experts on Immunization, October 2019:
https://www.merck.ca/static/pdf/GARDASIL_9-PM_E.pdf
2098
conclusions and recommendations. (2019).
Merck
Canada
Inc.
(2020).
PRODUCT
MONOGRAPH
GARDASIL®9.
2063
179. Public Health Agency of Canada.(2019). Public Health Agency of Canada. Canadaʼs
2099
Weekly Epidemiological Record. 2019, 94, 541‒560.
2064
Provincial and Territorial Routine (and Catch-up) Vaccination Schedule for Infants and
2100
https://www.who.int/wer/2019/wer9447/en/
2065
Children. https://www.canada.ca/content/dam/phac-aspc/documents/services/provincial-
2101
191.
2066
territorial-immunization-information/childhood-vaccination-schedule-august-2019.pdf
2102
(2019). 19th meeting of the European Technical Advisory Group of Experts on immunization
2067
180.
Patel, C., et al. (2018). The impact of 10 years of human papillomavirus (HPV)
2103
(ETAGE) (2019).
2068
vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
2104
https://www.euro.who.int/__data/assets/pdf_file/0009/424647/ETAGE-2019-report.pdf
2069
Euro Surveill 23(41).
2105
2070
181.
2071
Papillomavirus（HPV）.(2018). Factsheet Human Papillomavirus（HPV）.
2072
http://ncirs.org.au/ncirs-fact-sheets-faqs/human-papillomavirus-vaccine-australians
2073
182. Merck Sharp & Dohme (Australia) Pty Limited. (2017). PRODUCT INFORMATION
2074
GARDASIL®9. https://www.tga.gov.au/sites/default/files/auspar-human-papillomavirus-9-
2075
valent-vaccine-170103-pi.pdf
2076
183.
2077
(2017). Introduction of GARDASIL® 9 In a 2-Dose Schdule under the School-based National
The European Technical Advisory Group of Experts on Immunization (ETAGE).
National Centre for Immunisation Research and Surveillance. Factsheet Human
Australian Technical Advisory Group on Immunisation (ATAGI). Clinical Advice.
2078
Immunisation Program (NIP). https://www.health.gov.au/sites/default/files/atagi-advice-
2079
gardasil9.pdf
2080
184. The New Zealand Ministry of Health.HPV vaccine.
2081
https://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/hpv-
2082
immunisation-programme/hpv-vaccine
2083
185. The Immunisation Advisory Centre . Gardasil 9 Schedule and administration.
2084
https://www.immune.org.nz/vaccines/available-vaccines/gardasil-9
2085
186.
2086
SHEET GARDASIL® 9
Merck Sharp & Dohme (New Zealand) Limited. (2019).NEW ZEALAND DATA
2087
https://www.medsafe.govt.nz/profs/Datasheet/g/gardasil9inj.pdf
2088
187.
2089
Introduction of Vaccination to the National Immunization Program in Korea: an Overview. J
Kim, M. A., et al. (2018). Current Status of Human Papillomavirus Infection and
2090
Korean Med Sci 33(52): e331.
2091
188. Min, K. J., et al. (2019). Clinical guideline for 9-valent HPV vaccine: Korean Society
95
96